A106 USTEKINUMAB IS EFFECTIVE FOR MAINTAINING CLINICAL RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY

Ustekinumab for the treatment of moderate to severe psoriasis.

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of ustekinumab for the treatment of moderate to severe psoriasis based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's main evid...

Phase 3 Clinical Trials Support STELARA® (ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Is Training Contractors in Safety Issues Effective in Minimizing Occupational Accident Rates? A Retrospective Cohort Study

Background: Safety of contractors is one of the key safety challenges at construction. Safety training, as an essential prerequisite for achieving safety qualification certificates by contractors, could decrease accident rates in the construction. This study aims to evaluate the effectiveness of training construction contractors in safety issues in minimizing occupational accidents in a five-ye...

Economic and clinical benefits of ustekinumab in the treatment of moderate to severe psoriasis in Greece

Economic and clinical benefits of ustekinumab in the treatment of moderate to severe psoriasis in Greece Ioannis Bassukas, Georgios Chaidemenos, Andreas Katsampas, Marita Kosmadaki, Hara Kousoulakou, Athanasios Petridis, Brad Schenkel, Dimitrios Sotiriadis, Theofanis Spiliopoulos, Panagiotis Stavropoulos, Evgenia Toumpi, Loukas Xaplanteris. 1 Department of Skin and Venereal Diseases, University...

Demyelination in a patient receiving ustekinumab for refractory Crohn's disease.

Ustekinumab is a monoclonal antibody targeting the common part of interleukins 12 and 23, which has proven its efficacy in Crohn's disease1 and not in multiple sclerosis.2 Prevalence of autoimmune diseases including demyelinating disorders is increased in patients with inflammatory bowel disease (IBD)3 and cases of demyelination have been observed in patients receiving TNF-α antagonist. We repo...